Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 6/2006

01-06-2006 | Original Article

Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation

Authors: F. Atamaz, S. Hepguler, M. Akyildiz, Z. Karasu, M. Kilic

Published in: Osteoporosis International | Issue 6/2006

Login to get access

Abstract

Introduction

The purpose of this study was to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover markers in patients with orthotopic liver transplantation (OLT).

Methods

In the prospective, controlled, open study with 24 months of follow-up, 98 patients with OLT were randomised to receive ALN 70 mg weekly or no ALN; calcium (Ca) 1,000 mg daily and 0.5 mcg calcitriol daily were provided to all patients. Lumbar spine (LS) and hip BMDs were measured at 6-month intervals by dual-energy X-ray absorptiometry (DEXA). Spinal radiographs were obtained to assess vertebral fractures. Additionally, bone turnover markers, serum parathyroid hormone (PTH) and biochemical parameters were determined every 3 months.

Results

Compared with the control group, the ALN group showed significant increases in BMD of the LS (5.1±3.9% vs 0.4±4.2%, p<0.05 at 12 months, 8.9±5.7% vs 1.4±4.9%, p<0.05 at 24 months), femoral neck (4.3±3.8% vs −1.1±3.1%, p<0.05 at 12 months, 8.7±4.8% vs 0.6±4.5%, p<0.05 at 24 months) and total femur (3.6±3.8% vs −0.6±4.0%, p<0.05 at 12 months, 6.2±3.8% vs 0.3±4.6%, p<0.05 at 24 months). In the ALN group, osteocalcin and urinary deoxypyridinoline (DPD) decreased significantly at the sixth month, with no further change, by −35.6% and −63.0%, on average, respectively (p<0.05). In the control group, a significant increase in biochemical markers of bone turnover was observed in comparison to baseline values (p<0.05). PTH increased within reference levels without a difference between groups. Two nonvertebral fractures (4.2%) and nine vertebral fractures (18.8%) in the control group and three vertebral fractures (6.8%) in the ALN group occurred during the follow-up. The weekly ALN was well tolerated, and no severe side effects occurred.

Conclusion

This is the first randomised study including a control group to demonstrate that weekly ALN was able to significantly increase BMD in patients with OLT when compared with Ca and calcitriol alone. However, ALN did not appear to offer protection against fractures.
Literature
1.
Cheung AM (2001) Post-liver transplantation osteoporosis. J Hepatology 34:337–338CrossRef
2.
Delmas PD (2001) Osteoporosis in patients with organ transplants: a neglect problem. Lancet 357:325PubMedCrossRef
3.
4.
Ramsey- Goldman R, Dunn JE, Dunlop DD, et al (1999) Increased risk of fracture in patients receiving solid organ transplant. J Bone Miner Res 14:456–461PubMedCrossRef
5.
Crippin JS (2001) Bone disease after liver transplantation. Liver Transpl 7:27CrossRef
6.
Epstein S (1996) Post-transplantation bone disease. The role of immunsuppressive agents on the skeleton. J Bone Miner Res 11:1–7PubMed
7.
Smallwood GA, Wickman JM, Martinez E, et al (2002) Osteoporosis screening in an outpatient liver transplant clinic: Impact of primary immunsuppression. Transplant Proc 34:1569–1570PubMedCrossRef
8.
McDonald JA, Dunstan CR, Dilworth P, et al (1991) Bone loss after liver transplantation. Hepatology 14:613–619PubMed
9.
Porayko MK, Wiesner RH, Hay JE, et al (1991) Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc 23:1462–1465PubMed
10.
Riemens SC, Oostdijk A, van Doormaal JJ, et al (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidiol. Osteoporos Int 6:213–218PubMedCrossRef
11.
Eastell R, Dickson ER, Hodgson SF, et al (1991) Rates of vertebral bone loss before and after liver transplanttaion in women with primary biliary cirrhosis. Hepatology 14:296–300PubMedCrossRef
12.
Hochberg MC, Ross PD, Black D, et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246–1254PubMedCrossRef
13.
Shiraki M, Kushida K, Fukunaga M, et al (1998) A placebo-controlled, single blind study to determine to appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191–210PubMed
14.
Millonig G, Graziadei IW, Eichler D, et al (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 11(8):960–966PubMedCrossRef
15.
Genant HK, Wu CY, van Kuijk C, et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMed
16.
Wu CY, Li J, Jergas M, et al (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5(5):354–370PubMedCrossRef
17.
Genant HK, Jergas M, Palermo L, et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984–996PubMedCrossRef
18.
Sambrook P, Birmingham J, Kelly P, et al (1993) Prevention of corticosteroid osteoporosis-a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752PubMedCrossRef
19.
Cohen S, Levy RM, Keller M, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42(11):2309–2318PubMedCrossRef
20.
Adachi JD, Bensen WG, Brown J, et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387PubMedCrossRef
21.
Adachi JD, Bensen WG, Bianchi F, et al (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23:995–1000PubMed
22.
van den Ham EC, Kooman JP, Christiaans ML (2003) The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transp Int 16(2):82–87CrossRef
23.
Ninkovic M, Love S, Tom BD, et al (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37(1):93–100PubMedCrossRef
24.
Shane E, Thys- Jacobs S, Papadopoulos A, et al (1996) Antiresoptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res 11:635
25.
Fan S, Almond MK, Ball E, et al (1996) Randomised prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation. J Am Soc Nephrol 7:A2714
26.
Reeves HL, Francis RM, Manas DM, et al (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404–409PubMedCrossRef
27.
Dodidon P, Bruckner T, Hosch S, et al (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82–89CrossRef
28.
Monegal A, Navasa M, Guanabens N, et al (2001) Bone Disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484–497PubMedCrossRef
29.
Vedi S, Greer S, Skingle SJ, et al (1999) Mechanism of bone loss after liver transplantation: A histomorphometric analysis. J Bone Miner Res 1999 14(2):281–287CrossRef
30.
Feller RB, McDonald JA, Sherbon KJ, et al (1999) Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5:407PubMedCrossRef
31.
Crosbie OM, Freaney R, McKenna MJ, et al (1999) Predicting bone loss following orthotopic liver transplantation. Gut 44:430–434PubMedCrossRef
32.
Monegal A, Navasa M, Guanabens N, et al (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148–154PubMedCrossRef
Metadata
Title
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
Authors
F. Atamaz
S. Hepguler
M. Akyildiz
Z. Karasu
M. Kilic
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 6/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0082-5

Other articles of this Issue 6/2006

Osteoporosis International 6/2006 Go to the issue

Original Article

ALDH2 polymorphisms and bone mineral density in an elderly Japanese population

Original Article

A comparison between peripheral BMD and central BMD measurements in the prediction of spine fractures in men

Original Article

Lean mass plays a gender-specific role in familial resemblance for femoral neck bone mineral density in adult subjects

Original Article

Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture

Original Article

Unique and common genetic effects between bone mineral density and calcaneal quantitative ultrasound measures: the Fels Longitudinal Study

Original Article

Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone